Inogen (NASDAQ:INGN) Stock Breaks Below Two Hundred Day Moving Average on Disappointing Earnings

Inogen, Inc (NASDAQ:INGN) crossed below its two hundred day moving average during trading on Friday following a weaker than expected earnings announcement. The stock has a two hundred day moving average of $6.23 and traded as low as $5.05. Inogen shares last traded at $6.03, with a volume of 974,912 shares traded.

The medical technology company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The company had revenue of $77.19 million during the quarter, compared to analysts’ expectations of $92.25 million. Inogen had a negative net margin of 6.94% and a negative return on equity of 13.17%.

More Inogen News

Here are the key news stories impacting Inogen this week:

• Positive Sentiment: Inogen appointed Andy Reding as president and CEO and launched a $20 million cost-reduction program aimed at accelerating profitability. The savings could help improve results, though execution will be important. Inogen Announces Third Quarter 2026 Financial Results
• Neutral Sentiment: The company completed the sale of its U.S. oxygen rental business to Rotech on November 2. The divestiture changes the business mix, but the provided reports do not specify the sale’s financial impact. Leadership Transition and Cost-Reduction Program
• Neutral Sentiment: Trading in INGN was temporarily paused under a Limit Up-Limit Down (LULD) halt. The halt itself does not indicate the direction of the stock move.
• Negative Sentiment: Third-quarter revenue was $77.19 million versus analysts’ $92.25 million estimate, while loss per share was $0.56 versus an expected $0.14 loss—substantial misses that may weigh on investor confidence. Third-Quarter 2026 Financial Results
• Negative Sentiment: Inogen forecast FY 2026 revenue of $298 million–$301 million, far below the $356.4 million consensus. Its Q4 revenue outlook of $65 million–$68 million also trails the $84 million estimate, signaling a weaker near-term revenue outlook. Third-Quarter 2026 Financial Results

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Institutional Trading of Inogen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Inogen in the 2nd quarter valued at $11,281,000. Readystate Asset Management LP acquired a new position in shares of Inogen in the 2nd quarter worth approximately $1,718,000. Bank of New York Mellon Corp bought a new position in shares of Inogen during the second quarter valued at $764,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Inogen by 203.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company’s stock worth $3,622,000 after purchasing an additional 393,310 shares during the last quarter. Finally, Tocqueville Asset Management L.P. bought a new stake in shares of Inogen in the 2nd quarter worth about $602,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Stock Performance

The firm has a market cap of $160.04 million, a price-to-earnings ratio of -4.60 and a beta of 1.51. The business’s 50-day moving average is $5.96 and its 200-day moving average is $6.23.

Inogen Company Profile

Inogen, Inc is a medical technology company that develops, manufactures and markets portable oxygen concentrators for people who require long-term supplemental oxygen therapy. Its devices separate oxygen from ambient air and deliver concentrated oxygen without the need for traditional compressed-gas or liquid-oxygen tanks.

The company’s product portfolio has included the Inogen One portable oxygen concentrator line, as well as stationary and related oxygen therapy products. These systems are designed to support mobility and independence for patients with chronic respiratory conditions while offering features such as rechargeable batteries, portability and various oxygen-delivery settings.

Founded in 2001 and headquartered in Goleta, California, Inogen sells its products through direct-to-consumer channels, health-care providers, distributors and other commercial partners.